Multidisciplinary approach of early breast cancer: The biology applied to radiation oncology by Bourgier, Céline et al.
REVIEW Open Access
Multidisciplinary approach of early breast cancer:






Early breast cancer treatment is based on a multimodality approach with the application of clinical and histological
prognostic factors to determine locoregional and systemic treatments. The entire scientific community is strongly
involved in the management of this disease: radiologists for screening and early diagnosis, gynecologists, surgical
oncologists and radiation oncologists for locoregional treatment, pathologists and biologists for personalized char-
acterization, genetic counselors for BRCA mutation history and medical oncologists for systemic therapies.
Recently, new biological tools have established various prognostic subsets of breast cancer and developed predic-
tive markers for miscellaneous treatments.
The aim of this article is to highlight the contribution of biological tools in the locoregional management of early
breast cancer.
Introduction
Breast cancer is the most common female cancer in
France with increasing incidence over the last two dec-
ades and with decreasing mortality [1]. Systematic
screening can detects early breast cancers that are
potentially curable. All physicians are implicated in the
management of early breast cancer: radiologists for
screening and diagnosis; gynecologists, breast surgeons,
and radiation oncologists for locoregional treatment;
pathologists and biologists for individualized tumor
characterization; genetic counselors for BRCA mutation
history and medical oncologists for systemic therapies.
Recently, biological tools have identified different
prognostic subsets of breast cancers, and may predict
treatment efficacy [2-8].
This review highlights the contribution of biological
tools in a multidisciplinary approach, especially in locor-
egional treatment of early breast cancers.
Biological tools
The advent of biological tumor analysis has generated
information to classify prognostic features of breast can-
cer, and to assess treatment efficacy. Recently, several
classifications were identified defining the genomic
tumor characterization which include: (i) «intrinsic gene
signature» [2,3], (ii) tumor proliferation or invasion
[4-6], and (iii) tumor aggressiveness « wound signature;
invasive gene signature » [7,8]. At least three molecular
sets have therefore been suggested for breast cancer out-
comes: luminal (positive hormonal receptors - HR), tri-
ple negative (negative HR/ negative Her2), and Her2
overexpression phenotypes [2-4]. Other biological tools
have been developed to identify and classify those genes
implied in tumor progression and treatment response,
such as tissue micro arrays or comparative genomic
hybridization (CGH)-arrays. Furthermore, these tools
enable the detection of gene amplification or deletion
that can be targeted by new systemic therapies [9].
Differential diagnosis between benign and
malignant breast lesions: contribution of
biological tools
Recently, a new molecular classification based on differ-
ential expression of genes and exons has identified and
generated a molecular classifier for breast cancer diag-
nosis through differentially expressed exons in malig-
nant and benign breast lesions (accuracy 100% [IC95%:
96-100], sensitivity 100% [IC95%: 83-100%], and specifi-
city 100% [IC95%: 95-100] [10]. This molecular signa-
ture for breast cancer diagnosis with fine-needle
aspiration (FNA) is a promising biological tool owing to
its safer and quicker procedure [10,11]. The FNA proce-
dure has substantial advantages over core needle biopsy
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CNB for diagnosis of ACR grade 4 and 5 lesions and for
assessment of tissue and molecular signature. First, FNA
is a rapid and cost-effective tool for breast cancer diag-
nosis in a one-stop multidisciplinary breast clinic [12].
Moreover, FNA samples are more enriched in cancer
cells than CNB samples and thus, provide transcrip-
tional profiles of purer representation of the tumor-cell
population [10,13,14]. In contrast, the main advantage
of CNB compared to FNA is the ability to describe
tumor architecture but it is more expensive and time-
consuming [15].
Breast cancer chemotherapy and the contribution
of biological tools
The administration of systemic therapies is driven by
the assessment of clinical and/or pathological features
such as tumor size, nodal involvement, positive or nega-
tive hormonal receptors, and Her2 overexpression. How-
ever, none of these classical prognostic factors is able to
predict the response to treatment of breast cancers. The
advent of genomic technologies enables the improve-
ment of prognostic classification and accurate prediction
o fb e n e f i tf r o ms y s t e m i ct h e r a p i e sf o ri n d i v i d u a l
patients. The recent review of Di Leo et al. [16] analyzed
and detailed all these biological tools and their clinical
application, particularly in some ongoing clinical trials.
The contribution of biology and endocrine
therapies
Patients with hormonal receptor-positive breast cancers
receive endocrine therapy given over five consecutive
years, with either tamoxifen (TAM) in premenopausal
women, or aromatase inhibitors (AI) or sequential endo-
crine therapy in postmenopausal women [17]. To deter-
mine which endocrine therapy would benefit a selected
patient population is not feasible in daily practice. In
this context, biological tools may identify patients in
whom AI or TAM as initial endocrine therapy would be
of benefit. Recently, Viale et al. have assessed the prog-
nostic and predictive value of Ki-67 labeling index in
the Breast International Group (BIG) trial 1-98. A high
Ki-67 labeling index level was correlated to a worse dis-
ease-free survival (DFS), and patients treated by AI had
an enhanced DFS compared to patients treated by
TAM. The Ki-67 labeling index level could therefore
identify a subgroup of patients who would benefit from
initial AI endocrine therapy [18].
Contribution of biology in adjuvant radiotherapy
of early breast cancer
Biological technologies have been largely developed for
classifying breast cancers after systemic therapies, and
for predicting the efficacy of systemic therapies, whereas
biological contribution in the field of locoregional treat-
ment is less developed. Biological applications are war-
ranted to optimize local control for breast cancer
patients at high risk of local relapse. Furthermore, these
biological tools would identify patients at high risk of
late radiation-induced toxicity.
Biological tools: To determine breast cancer patients at
high risk of local relapse
The current locoregional management of early breast
cancer consists of breast conserving surgery (i.e., lum-
pectomy and sentinel node biopsy or axillary dissection)
followed by whole-breast irradiation (WBI, 50 Gy in 25
fractions over 5 weeks) and then a boost of 10-16 Gy to
the tumor bed. WBI significantly reduces local relapse
by a factor of two with an absolute gain in local relapse
rate of 20% at 15 years, corresponding to a survival ben-
efit of 5% [19]. The boost to the tumor bed contributes
to a decrease in the local relapse risk of 50% whatever
the patients’ age [20-22].
While adjuvant radiotherapy plays a crucial part in the
locoregional management of early breast cancer, local
relapse still occurs. These local relapses are an indepen-
dent factor for distant metastatic relapse [23] and for
specific cancer mortality [24]. A number of clinical and
histological parameters are usually described as prognos-
tic factors for locoregional relapse such as young age,
positive or close margins, extensive DCIS [25-28], high
tumor grade, presence of vascular embolus and/or lym-
phovascular invasion (LVI), and tumor size [29-31].
However, none of these parameters are able to predict
which patients are at high risk of locoregional relapse.
Recently, a computer-based tool “IBTR !” attempted to
predict local relapse in women with invasive breast can-
cer after breast conserving surgery. This nomogram is
only valid for patients presenting low risk of local recur-
rence [32,33]. As clinical, histological, and computer-
based tools are not sufficient to predict local relapse,
prognostic and predictive biological factors are needed.
A tissue-micro-array has been built, based on an “intrin-
s i cg e n es i g n a t u r e ” showing that Her2 overexpression
and basal-like breast cancer subtypes were prognostic
factors for local relapse [34]. Other genomic classifica-
tions could be used to determine the risk of local
relapse after breast conserving surgery, such as “wound
signature” [35].
A history of BRCA1/2 mutation is related to a higher
lifetime risk of developing breast cancer and breast con-
serving treatment remains debatable in this patient
population owing to the residual presence of breast tis-
sue which still contains all remaining cells carrying the
same deleterious mutations. The BRCA1/2 mutation is
not yet a targeted tool to determine a population of
breast cancer at high risk of local relapse. The molecular
pathway involved in DNA repair, particularly the role of
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resistance to ionizing radiation (IR) in case of BRCA1/2
mutation, due to underlying in vitro effects. An incor-
rect repair of DNA double-strand breaks after IR, due to
BRCA1/2 mutation, could lead to the development of
new primary breast cancer. On the other hand, the in
vitro effects of IR on BRCA1/2 cell lines showed an
increased radiosensitivity [36,37], partially related to the
loss of bcl-2 expression after IR, leading to an increased
radiation-induced apoptosis [38]. Clinical data suggest
that BRCA1/2 carriers have a similar local and overall
outcome to non-carriers whatever radical or conserva-
tive local treatment has been performed [39,40].
Biological tools: a need for combined therapies
Breast cancer cell lines that overexpressed Her2 onco-
protein are known to be resistant to IR. When trastuzu-
mab was combined with IR, an enhancement of in vitro
and in vivo tumor radiosensitization was observed,
through DNA repair inhibition and through an
increased tumor cell death [41,42]. Recently, the addi-
tion of trastuzumab to radiotherapy has been shown to
be an effective radiosensitizer in patients with Her2
overexpression, with chemotherapy-refractory disease,
locally-advanced or recurrent breast cancer in a phase II
trial. Although these breast cancers were initially consid-
ered to be inoperable, breast surgery could be per-
formed in 58% of patients with a substantial pathologic
response (complete response or microscopic residual
disease) in 43% of patients [43].
Biological tools: To a personalized radiosensitivity of
normal tissues
Different parameters could be involved in the develop-
ment of late radiation-induced toxicity, such as genetic
factors (DNA repair deficiency) or epigenetic factors
(obesity, vascular, or collagen diseases...). Other issues
c o u l da l s ob ei n v o l v e di nr a d iation-induced toxicities
such as radiotherapy parameters (total dose, dose per
fraction, irradiated target and normal tissue volumes),
history of surgery within irradiated fields, and the com-
bination of either chemotherapy or endocrine therapy
with radiation therapy.
Recently, a nomogram was built to predict the risk of
fibrosis after breast-conserving therapy [44]. This com-
puter-based tool allocated points according to various
factors such as age, postoperative hematoma, breast
edema, the use (concomitant or not) of tamoxifen and/
or chemotherapy, radiotherapy parameters (photon
energy [6 MV or more], electron or photon boost,
energy of electron boost in case of electron use, maxi-
mal total dose). The main limitation for daily use of this
nomogram is that this computer-based tool cannot
identify a population at high risk of severe late radia-
tion-induced toxicities. Indeed, when usual radiotherapy
parameters were considered, i.e., 6-MV photons, a total
dose of 66 Gy and photon beam boost, the nomogram
predicts an over-risk of fibrosis of 50% at 10 years. This
over-risk is larger than observed fibrosis after breast
conserving therapy.
Biological predictive factors are warranted to identify
the individual risk of development of severe late toxicity.
A lymphocyte apoptosis assay has been developed as a
rapid tool for characterization of normal tissue radiosen-
sitivity, particularly due to the ease of blood collection
in a standardized, patient-friendly manner [45-47].
Severe late radiation-induced toxicities (grade 2 or
more) were correlated to a low rate of radiation-induced
CD8 T-lymphocyte apoptosis (≤ 16%) [48,49]. In addi-
tion, patients with severe late effects possessed four or
more SNPs (Single Nucleotide Polymorphisms) in candi-
date genes (ATM, TGFB1, XRCC1, XRCC3, SOD2, and
RAD21) [48].
Conclusion
Biological tools can play a part in each step of the man-
agement of early breast cancer from diagnosis to treat-
ment; i.e., surgery, adjuvant radiotherapy, and systemic
therapies. Currently used biological tools for prognostic
classification or for predicting systemic treatment effi-
cacy, could be applied for locoregional treatments to
predict antitumor efficacy. In addition, radiation oncolo-
gists have developed new tools focusing on normal tis-
sue radiosensitivity that may be adapted to systemic
therapies in the near future. Dedicated prospective stu-
dies are urgently warranted in this setting.
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